DM
Migliorini, Denis
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade | Cellular and molecular life sciences |  | 2025 | 78 | 22 | ||
| Magnetic bead-sensitized optoporation coupled with antibodies-based activation for mRNA CAR-T cell manufacturing | Molecular therapy. Methods & clinical development | | 2025 | 29 | 22 | ||
| Surgical and clinical impacts of mixed reality-guided glioblastoma resection versus standard neuronavigation: improving tumor surgery | Frontiers in oncology | | 2025 | 19 | 12 | ||
| Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure | Nature cancer | | 2025 | 31 | 146 | ||
| PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | | 2024 | 254 | 219 | ||
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | | 2024 | 85 | 85 | ||
| A novel mitochondrial pyruvate carrier inhibitor drives stem cell-like memory CAR T cell generation and enhances antitumor efficacy | Molecular therapy. Oncology | | 2024 | 101 | 87 | ||
| Corticosteroid therapy in older adults with cancer : Expert recommendations from a task force of the International Society of Geriatric Oncology | Journal of geriatric oncology |  | 2024 | 12 | 0 | ||
| A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol | BMC cancer | | 2024 | 132 | 51 | ||
| Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages | Cell communication and signaling | | 2024 | 109 | 37 | ||
| Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial | Nature cancer | | 2024 | 276 | 3 | ||
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance | Cancer research communications | | 2023 | 114 | 33 | ||
| ChatGPT in glioma adjuvant therapy decision making: ready to assume the role of a doctor in the tumour board? | BMJ health & care informatics | | 2023 | 136 | 46 | ||
| An Overview of Cytokine Release Syndrome and Other Side Effects of CAR-T Cell Therapy | Praxis | | 2023 | 103 | 0 | ||
| Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | New England journal of medicine | | 2023 | 216 | 203 | ||
| Reductive carboxylation epigenetically instructs T cell differentiation | Nature | | 2023 | 142 | 0 | ||
| PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma | | 2023 | 179 | 400 | |||
| The potential role of the microbiota in prostate cancer pathogenesis and treatment | Nature reviews. Urology | | 2023 | 90 | 0 | ||
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | | 2023 | 292 | 70 | ||
| Incidence of cisplatin-induced ototoxicity in adult cancer patients based on audiometric confirmation of patient self-report | Frontiers in audiology and otology | | 2023 | 110 | 147 | ||
| c-Met+ Cytotoxic T Lymphocytes Exhibit Enhanced Cytotoxicity in Mice and Humans In Vitro Tumor Models | Biomedicines | | 2023 | 20 | 18 | ||
| Novel pathophysiological insights into CAR-T cell associated neurotoxicity | Frontiers in neurology | | 2023 | 140 | 60 | ||
| Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy | Nature cancer | | 2023 | 235 | 294 | ||
| Cancer vaccines | Cancer cell | | 2022 | 271 | 125 | ||
| The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function | Cell metabolism | | 2022 | 690 | 239 | ||
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | 2022 | 69 | 82 | ||
| Clinical relevance of tumour-associated macrophages | Nature reviews. Clinical oncology | | 2022 | 476 | 1 | ||
| CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives | Biomedicines | | 2022 | 198 | 127 | ||
| Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis | Diagnostics | | 2022 | 83 | 47 | ||
| Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis | Journal of neuro-oncology | | 2022 | 236 | 1 | ||
| Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies | International Journal of Molecular Sciences | | 2021 | 235 | 164 | ||
| Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma | Frontiers in Immunology | | 2021 | 432 | 273 | ||
| Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread | Neurology Genetics | | 2021 | 306 | 72 | ||
| Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells | Human gene therapy | | 2021 | 184 | 0 | ||
| Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM) | Swiss Medical Weekly | | 2021 | 273 | 128 | ||
| From Focused Ultrasound Tumor Ablation to Brain Blood Barrier Opening for High Grade Glioma: A Systematic Review | Cancers (Basel) | | 2021 | 223 | 141 | ||
| Cellules CAR-T pour le traitement des tumeurs solides : présent et futur | Revue médicale suisse | | 2021 | 321 | 282 | ||
| Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors | International Journal of Molecular Sciences | | 2020 | 270 | 177 | ||
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | | 2020 | 464 | 277 | ||
| Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients | Frontiers in Oncology | | 2020 | 315 | 109 | ||
| Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies | Cell | | 2020 | 369 | 0 | ||
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | | 2019 | 796 | 411 | ||
| Current strategies for vaccination in glioblastoma | Current Opinion in Oncology | | 2019 | 381 | 5 | ||
| Actively personalized vaccination trial for newly diagnosed glioblastoma | Nature | | 2019 | 524 | 12 | ||
| Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients | Cancers | | 2019 | 353 | 164 | ||
| CAR T-Cell Therapies in Glioblastoma: A First Look | Clinical Cancer Research | | 2018 | 570 | 2 | ||
| Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development | ILAR journal | | 2018 | 196 | 0 | ||
| Glycan-directed CAR-T cells | Glycobiology | | 2018 | 213 | 0 | ||
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | | 2018 | 646 | 300 | ||
| BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma | Neurology | | 2017 | 529 | 194 | ||
| First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies | OncoImmunology | | 2017 | 624 | 9 | ||
| Rapidly Growing Pulmonary Metastasis from Anaplastic Meningioma with Lethal Outcome: A Case Report | Journal of Neurological Surgery Reports | | 2017 | 541 | 184 | ||
| Immunothérapie des gliomes : illusion ou espoir ? | Bulletin du cancer | 2017 | 399 | 0 | |||
| Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Frontiers in Oncology | | 2016 | 506 | 398 | ||
| Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes | Journal of neuro-oncology | | 2016 | 504 | 423 | ||
| Progrès dans l'immunothérapie des tumeurs cérébrales : difficultés et perspectives | Revue médicale suisse | | 2016 | 329 | 2 | ||
| Medulloblastoma in children and adults: one distinct disease entity? | Bulletin suisse du cancer | | 2016 | 474 | 55 | ||
| Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review | CNS oncology | 2015 | 486 | 0 | |||
| Lymphome cérébral : une présentation classique ? | Revue médicale suisse | | 2015 | 373 | 436 | ||
| Immunotherapy of Brain Tumors | Progress in tumor research | 2015 | 565 | 0 | |||
| The CD40/CD40L axis in glioma progression and therapy | Neuro-oncology | | 2015 | 480 | 174 | ||
| Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies | Immunotherapy |  | 2013 | 523 | 0 |
